Hematology

High response rates were seen in patients that would not meet ZUMA-2 eligibility criteria.

No differences were found in overall survival and progression free survival across races.

Review top news and interview highlights from the week ending June 3, 2022.

A recent meta-analysis reviewed data across 146 patients in 9 clinical trials.

Relma-cel was previously approved in China in September 2021 for the treatment of B-cell non-Hodgkin lymphoma.

Beti-cel was rated a B+ for lingering questions about durability and unknown risks.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

BioMarin now expects to file in September 2022 instead of June.

Treated patients had significant improvements in fatigue and lymphoma symptoms.

The approval was based on data from the phase 2 ELARA clinical trial, in which a complete response of more than 65% was observed.

The director of the Center for Multiple Myeloma and Mass Gen discussed unmet needs with CAR T-cell therapy in multiple myeloma.

Review top news and interview highlights from the week ending May 27, 2022.

The chief executive officer of Ring Therapeutics, Tuyen Ong, MD, discussed the potential of anellovirus vectors for use in gene therapy.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

A final analysis of the pivotal HOPE-B study was presented at ASGCT 2022.

The clinical professor of pediatrics at Stanford Medicine discussed positive interim findings from a phase 1 study of RP-L301.

Review top news and interview highlights from the week ending May 20, 2022.

Findings from a preclinical study, which are in contrast with the current biphasic recovery model, have implications for both HSC transplantation and gene therapy.

The assistant professor of oncology at UNC School of Medicine discussed the first-in-human study being conducted with CT-0508.

Investigators from Seattle Children’s Hospital found that engineered T-cell regulatory products demonstrated significant suppression of effector T cells.

The trial met its primary efficacy end point, and participants reported improvements in quality-of-life factors such as outlook on the future and feelings about having hemophilia.

Catch up on the latest news and announcements in cell and gene therapies presented at the annual ASGCT meeting.

In a late-breaking presentation at ASGCT 2022, investigators shared preclinical results of a gene-editing strategy that seeks to reactivate developmentally silenced fetal hemoglobin (HbF, α2γ2) in order to replace defective sickle hemoglobin (HbS, α2βS2).

Further data from Mustang Bio’s phase 1/2 trial will be presented at the EHA 2022 Congress.

Review top news and interview highlights from the week ending May 13, 2022.